PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10628359-1	1999	Our recent study has demonstrated that ponalrestat, an aldose reductase inhibitor, activates lipoprotein lipase (LPL) activity in the adipose tissue and alleviates the cachectic symptoms induced by B16 melanoma in mice.	ponalrestat	39-50	lipoprotein lipase	Mus musculus	93-111	
10628359-1	1999	Our recent study has demonstrated that ponalrestat, an aldose reductase inhibitor, activates lipoprotein lipase (LPL) activity in the adipose tissue and alleviates the cachectic symptoms induced by B16 melanoma in mice.	ponalrestat	39-50	lipoprotein lipase	Mus musculus	113-116	
10628360-1	1999	Our recent study has demonstrated that B16 melanoma-induced cachexia in mice is inhibited by ponalrestat, an aldose reductase inhibitor, which has the ability to activate lipoprotein lipase (LPL) activity both in vitro and in vivo.	ponalrestat	93-104	lipoprotein lipase	Mus musculus	171-189	
10628360-1	1999	Our recent study has demonstrated that B16 melanoma-induced cachexia in mice is inhibited by ponalrestat, an aldose reductase inhibitor, which has the ability to activate lipoprotein lipase (LPL) activity both in vitro and in vivo.	ponalrestat	93-104	lipoprotein lipase	Mus musculus	191-194	
10226565-0	1999	Activation of lipoprotein lipase and inhibition of B16 melanoma-induced cachexia in mice by ponalrestat, an aldose reductase inhibitor.	ponalrestat	92-103	lipoprotein lipase	Mus musculus	14-32	
10226565-3	1999	During a screening program for anti-cachectic agents we found that ponalrestat, an aldose reductase inhibitor, activates LPL activity.	ponalrestat	67-78	lipoprotein lipase	Mus musculus	121-124	
10226565-4	1999	Ponalrestat increased the activity of LPL in adipose tissue in mice.	ponalrestat	0-11	lipoprotein lipase	Mus musculus	38-41	
10226565-10	1999	Overall, this study demonstrated that ponalrestat, an aldose reductase inhibitor, possesses potent LPL activating activity and that the cachexia induced by B16 melanoma was alleviated by treatment with "ponalrestat, suggesting that ponalrestat, a LPL activating agent, has a therapeutic potential for the treatment of cancer cachexia.	ponalrestat	38-49	lipoprotein lipase	Mus musculus	99-102	
10226565-10	1999	Overall, this study demonstrated that ponalrestat, an aldose reductase inhibitor, possesses potent LPL activating activity and that the cachexia induced by B16 melanoma was alleviated by treatment with "ponalrestat, suggesting that ponalrestat, a LPL activating agent, has a therapeutic potential for the treatment of cancer cachexia.	ponalrestat	38-49	lipoprotein lipase	Mus musculus	247-250	
10226565-10	1999	Overall, this study demonstrated that ponalrestat, an aldose reductase inhibitor, possesses potent LPL activating activity and that the cachexia induced by B16 melanoma was alleviated by treatment with "ponalrestat, suggesting that ponalrestat, a LPL activating agent, has a therapeutic potential for the treatment of cancer cachexia.	ponalrestat	203-214	lipoprotein lipase	Mus musculus	247-250	
10226565-10	1999	Overall, this study demonstrated that ponalrestat, an aldose reductase inhibitor, possesses potent LPL activating activity and that the cachexia induced by B16 melanoma was alleviated by treatment with "ponalrestat, suggesting that ponalrestat, a LPL activating agent, has a therapeutic potential for the treatment of cancer cachexia.	ponalrestat	203-214	lipoprotein lipase	Mus musculus	247-250